- Home
- AEON vs KALA Comparison
AEON vs KALA Comparison
Compare AEON & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEON | KALA |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0M | 21.8M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | AEON | KALA |
|---|---|---|
| Price | $0.40 | $1.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.20 | ★ $31.50 |
| AVG Volume (30 Days) | 50.8K | ★ 191.5K |
| Earning Date | 05-14-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.48 | $0.07 |
| 52 Week High | $1.45 | $20.58 |
Technical Indicators
Market Signals| Indicator | AEON | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 18.98 | 31.44 |
| Support Level | N/A | $0.18 |
| Resistance Level | $0.75 | $1.81 |
| Average True Range (ATR) | 0.05 | 0.30 |
| MACD | -0.03 | -0.17 |
| Stochastic Oscillator | 0.74 | 2.02 |
Price Performance
Historical ComparisonAbout AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
About KALA KALA BIO Inc.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.